{"filing":{"accession_number":"0001193125-26-302098","cik":"0001776111","ticker":"MBX","company_name":"MBX Biosciences, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"d143977d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526302098/d143977d8k.htm"},"events":[{"id":17639,"run_id":15807,"accession_number":"0001193125-26-302098","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Kent P. Hawryluk's departure as Chief Executive Officer and Board member effective July 13, 2026 is the opening and most prominent disclosure in this Item 5.02. While the filing also covers two executive appointments (Hoerter as CEO and Smither as CFO) with compensatory arrangements, the departure of the sitting CEO is the principal event that would materially affect investor assessment of the company's leadership continuity and governance.","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16190,"accession_number":"0001193125-26-302098","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Kent P. Hawryluk's departure as Chief Executive Officer and Board member effective July 13, 2026 is the opening and most prominent disclosure in this Item 5.02. While the filing also covers two executive appointments (Hoerter as CEO and Smither as CFO) with compensatory arrangements, the departure of the sitting CEO is the principal event that would materially affect investor assessment of the company's leadership continuity and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:47:37.017292+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16190,"accession_number":"0001193125-26-302098","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Kent P. Hawryluk's departure as Chief Executive Officer and Board member effective July 13, 2026 is the opening and most prominent disclosure in this Item 5.02. While the filing also covers two executive appointments (Hoerter as CEO and Smither as CFO) with compensatory arrangements, the departure of the sitting CEO is the principal event that would materially affect investor assessment of the company's leadership continuity and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:47:37.017292+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-07-13"}]}